Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Continuing Exposure to Low-Dose Nonylphenol Aggravates Adenine-Induced Chronic Renal Dysfunction and Role of Rosuvastatin Therapy

Figure 1

Serial changes of serum levels of creatinine and blood urea nitrogen and the ratio of urine protein to creatinine at the end of study period. Serial changes in serum levels of blood urine nitrogen (BUN) (A) and creatinine (C) in different groups of rats after adenine-induced chronic kidney disease (CKD). B) By 24-week, remarkably increased serum levels of BUN in adenine (AD)-treated (group 3) rats than in normal (group 1) and Nonylphenol (NP)-treated (group 2) rats. Markedly increased BUN levels in adenine + NP-treated (group 4) rats than in other groups, but significantly reduced in adenine + NP-treated rats receiving rosuvastatin (Rosu) (group 5) than in group 4. D) Similar changes in serum creatinine levels compared to those of BUN by 24-week after CKD induction. Statistical analysis by one-way ANOVA. For BUN and creatinine: * vs. other groups, p < 0.0001 (at 24 week). For A & C): ¶ indicated AD + NP group vs. other groups (at 16, 20 and 24 weeks), p < 0.01. For E) (the ratio of urine protein to creatinine): * vs. other groups with different symbols (†, ‡, §), p < 0.0001. Symbols (*, †, ‡, §) indicate significance (at 0.05 level by Scheffe multiple-comparison post hoc test) (n = 10 in each group).

Back to article page